Jing Tian Biotech's Two Major New Drugs Enter Mid-to-Late Stage Clinical Trials, Aiming for Licensing Cooperation
NQ Score
80/100
AI Summary (NQ-processed)
Jing Tian Biotech's two new drugs, APC101 pain relief spray and APC201 anti-inflammatory foam, have entered mid-to-late stage clinical trials. International pharmaceutical companies have proactively inquired about cooperation opportunities. The company is pursuing a dual-engine strategy of new drug licensing and co-development to expand its operations.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What new drugs is Jing Tian Biotech developing?
- A: Jing Tian Biotech is developing two new drugs: APC101 pain relief spray and APC201 anti-inflammatory foam.
- Q: What stage are Jing Tian Biotech's new drugs in?
- A: Both new drugs are in mid-to-late stage clinical trials, with APC101 in Phase 2b and Phase 3, and APC201 planning global multi-center Phase 2b and Phase 3 clinical trials.